

#### **Source**

Anti-Rituximab Antibody (AY37) is a Mouse monoclonal antibody produced from a hybridoma created by fusing SP2/0 myeloma and Mouse B-lymphocytes.

Clone

AY37

**Species** 

Mouse

Isotype

Mouse IgG1/kappa

**Antibody Type** 

Hybridoma Monoclonal

Reactivity

Human

Immunogen

Rituximab.

**Specificity** 

Recognizes Rituximab specifically, no cross reactivity with other humanized antibodies.

## **Application**

ELISA 0.6-312.5 ng/mL

### **Purity**

>95% as determined by SDS-PAGE.

#### **Purification**

Protein A purified/ Protein G purified

#### **Formulation**

Lyophilized from  $0.22~\mu m$  filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.

Contact us for customized product form or formulation.

#### Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

# Storage


For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

- 4-8°C for 12 months in lyophilized state;
- -70°C for 12 months under sterile conditions after reconstitution.

# **SDS-PAGE**



Anti-Rituximab Antibody (AY37) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein








is greater than 95%.

## **Bioactivity-ELISA**

0.001


0.01



Rituximab Conc. (μ g/ml)


Detection of rituximab by bridging ELISA in serum. Immobilized Anti-Rituximab Antibody (AY37) (Cat. No. RIB-Y37) at 2  $\mu$ g/mL, add increasing concentrations of rituximab (10% human serum) and then add Biotinylated Anti-Rituximab Antibody (Cat. No. RIB-BY35) at 1  $\mu$ g/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 1 ng/mL (QC tested).

# **Bioactivity-FACS**



FACS analysis shows that the binding of rituximab to 293F overexpressing CD20 was inhibited by increasing concentration of Anti-Rituximab Antibody (AY37) (Cat. No. RIB-Y37). The concentration of rituximab used is 10 ng/ml. The IC50 is 0.019 µg/ml (Routinely tested).

#### **Determination of Anti-Rituximab Antibodies Specificity**



Demonstration of the specificity of Anti-Rituximab Antibody (AY37) (Cat. No. RIB-Y37) to the rituximab.

### **Background**

Rituxan is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light- and heavy-chain variable region sequences and human constant region sequences. Rituximab is composed of two heavy chains of 451 amino acids and two light chains of 213 amino acids

#### **Clinical and Translational Updates**

